CIITA (Class II Major Histocompatibility Complex Transactivator) is the master transcriptional coactivator that controls the expression of MHC class II genes, making it essential for adaptive immune responses["@boss2003"]. While primarily studied in immune cells, CIITA has emerged as a relevant player in neuroinflammation and neurodegenerative through its regulation of antigen presentation in the brain["@meda1995"]. The protein functions as a non-DNA-binding coactivator that orchestrates the assembly of transcription factors at MHC class II promoters.
Gene Information
Protein Structure
CIITA (~1130 amino acids) contains several functional domains:
N-terminal acidic domain: Mediates interactions with transcriptional coactivators and chromatin remodelers
Proline/serine/threonine-rich (PST) region: Functions in transcriptional activation
GTP-binding domain: Unique among transcriptional coactivators, this domain is functionally important
C-terminal leucine-rich repeats (LRR): Involved in protein-protein interactions[@boss2003]
The structure allows CIITA to serve as a molecular scaffold, recruiting multiple transcriptional machinery components to MHC class II promoters.
Function
MHC Class II Expression
CIITA is absolutely required for MHC class II gene transcription:
Master regulator: CIITA expression correlates directly with MHC class II expression[@boss2003]
Promoter recruitment: CIITA recruits RFX5, CREB, and NF-Y to MHC class II promoters[@muhlethalermottet2008]
Chromatin remodeling: CIITA interacts with histone acetyltransferases (p300/CBP) and chromatin remodelers (SWI/SNF) to enable transcription[@kwon2003]
Immune Cell Functions
Dendritic cells: CIITA is essential for antigen presentation to CD4+ T cells
B cells: Required for proper B cell maturation and function
Macrophages: Controls MHC class II expression in activated macrophages
Non-Immune Cell Expression
Under certain conditions, CIITA can be expressed in non-immune cells:
Endothelial cells: Can express MHC class II in response to IFN-γ
Tumor cells: Sometimes expressed in cancer cells
Neural cells: Limited expression in brain under inflammatory conditions[@meda1995]
Role in Neurodegenerative Diseases
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease), CIITA contributes to neuroinflammation:
Microglial MHC class II: CIITA drives MHC class II expression on [microglia](/cell-types/microglia-neuroinflammation), enabling antigen presentation to T cells[@mcmanus2020]
Chronic neuroinflammation: Sustained CIITA expression contributes to the pro-inflammatory milieu
Adaptive immunity activation: MHC class II expression may enable T cell-mediated responses in AD brain[@gate2020]
Therapeutic implications: Modulating CIITA could influence the neuroinflammatory environment[@meda1995]
Parkinson's Disease
CIITA involvement in PD includes:
Dopaminergic neuron vulnerability: CIITA expression in surrounding glial cells may contribute to inflammatory attack on dopaminergic [neurons](/entities/neurons)[@brochard2009]
[Blood-brain barrier](/entities/blood-brain-barrier): MHC class II expression on endothelial cells may affect immune cell trafficking[@takeshita2020]
[α-Synuclein](/proteins/alpha-synuclein) immunity: CIITA may influence how the immune system responds to α-synuclein pathology
Amyotrophic Lateral Sclerosis
In ALS, CIITA plays significant roles:
T cell infiltration: CIITA-mediated MHC class II expression enables CD4+ T cell involvement in ALS pathogenesis[@chiu2008]
Glial activation: Astrocyte and microglial MHC class II expression is elevated in ALS
Autoimmunity: Some evidence suggests CIITA polymorphisms may affect ALS risk
Neuroinflammation: CIITA drives the inflammatory environment that damages motor neurons[@chiu2008]
Multiple Sclerosis
While not a primary neurodegenerative disease, MS provides insights into CIITA's role in neuroinflammation:
Demyelination: CIITA expression correlates with lesion activity
Therapeutic targeting: Medications that modulate CIITA (e.g., interferon-beta) are used to treat MS[@bencimon2005]
Expression in the Brain
In the central nervous system, CIITA expression is typically low but inducible:
Microglia: Primary source of CIITA in the brain under inflammatory conditions
[Astrocytes](/entities/astrocytes): Can express CIITA in response to cytokines
Neurons: Generally do not express CIITA or MHC class II
[Boss JM, Jensen PE, Transcriptional regulation of the MHC class II antigen presentation pathway (2003)](https://pubmed.ncbi.nlm.nih.gov/12495738/)
[Meda L, et al, MHC class II expression in Alzheimer's disease brain (1995)](https://pubmed.ncbi.nlm.nih.gov/8544874/)
[Muhlethaler-Mottet A, et al, The master regulator CIITA: A network controlling MHC class II gene expression (2008)](https://pubmed.ncbi.nlm.nih.gov/17451833/)
[Kwon JA, et al, CIITA and chromatin remodeling (2003)](https://pubmed.ncbi.nlm.nih.gov/12847068/)
[McManus RM, et al, MHC class II expression in Alzheimer's disease microglia (2020)](https://pubmed.ncbi.nlm.nih.gov/33246473/)
[Gate D, et al, T cells in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32839653/)
[Brochard V, et al, Infiltration of CD4+ lymphocytes in Parkinson's disease brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19693542/)
[Takeshita Y, et al, Blood-brain barrier dysfunction in neurodegenerative (2020)](https://pubmed.ncbi.nlm.nih.gov/32061791/)
[Chiu IM, et al, T cells from ALS patients respond to disease antigens (2008)](https://pubmed.ncbi.nlm.nih.gov/20368173/)
[Bencimon C, et al, MHC class II in multiple sclerosis: A new marker for disease progression (2005)](https://pubmed.ncbi.nlm.nih.gov/15824344/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Class II Major Histocompatibility Complex Transactivator discovered through SciDEX knowledge graph analysis: